Table 1. Patient characteristics among 17 038 adults initiating public-sector antiretroviral therapy (ART) by CD4 count at ART initiation, 2008–2012.
| Baseline characteristic | CD4<50 cells/μL (n=3145) | CD4 50–99 cells/μL (n=2934) | CD4 100–199 cells/μL (n=6850) | CD4 200–299 cells/μL (n=2954) | CD4≥300 cells/μL (n=1155) | Total (n=17 038) |
|---|---|---|---|---|---|---|
| Cohort | ||||||
| Hlabisa (1) | 1440 (45.8) | 1437 (49.0) | 3364 (49.1) | 1190 (40.3) | 859 (74.4) | 8290 (48.7) |
| Khayelitsha (2) | 841 (26.7) | 925 (31.5) | 2406 (35.1) | 1398 (47.3) | 194 (16.8) | 5764 (33.8) |
| Themba Lethu (3) | 864 (27.5) | 572 (19.5) | 1080 (15.8) | 366 (12.4) | 102 (8.8) | 2984 (17.5) |
| Gender | ||||||
| Female | 1700 (54.1) | 1767 (60.2) | 4696 (68.6) | 2172 (73.5) | 908 (78.6) | 11 243 (66.0) |
| Age (years) | ||||||
| Median (IQR) | 35.2 (30.0–41.7) | 35.6 (29.9–42.4) | 35.3 (29.8–42.7) | 34.5 (28.9–41.3) | 35.3 (29.0–43.2) | 35.2 (29.6–42.2) |
| 16–24 | 197 (6.3) | 202 (6.9) | 527 (7.7) | 263 (8.9) | 131 (11.3) | 1320 (7.8) |
| 25–34 | 1351 (43.0) | 1185 (40.4) | 2801 (40.9) | 1282 (43.4) | 440 (38.1) | 7059 (41.4) |
| 35–44 | 1072 (34.1) | 1000 (34.1) | 2166 (31.6) | 949 (32.1) | 344 (29.8) | 5531 (32.5) |
| ≥45 | 535 (16.7) | 547 (18.6) | 1356 (19.8) | 460 (915.6) | 240 (20.8) | 3128 (18.4) |
| Year of ART initiation | ||||||
| 2008 | 1089 (34.6) | 918 (31.3) | 1977 (28.9) | 601 (20.4) | 132 (11.4) | 4717 (27.7) |
| 2009 | 1061 (33.7) | 938 (32.0) | 2165 (31.6) | 781 (26.4) | 199 (17.2) | 5144 (30.2) |
| 2010 | 615 (19.6) | 663 (22.6) | 1632 (23.8) | 808 (27.4) | 309 (26.8) | 4027 (23.6) |
| 2011 | 358 (11.4) | 386 (13.2) | 980 (14.3) | 615 (20.8) | 366 (31.7) | 2705 (15.9) |
| 2012 | 22 (0.7) | 29 (1.0) | 96 (1.4) | 149 (5.0) | 149 (12.9) | 445 (2.6) |
| WHO stage | ||||||
| I and II | 342 (18.9) | 595 (32.1) | 2260 (50.1) | 1209 (55.6) | 321 (49.8) | 4727 (43.0) |
| III | 1011 (55.9) | 938 (50.6) | 1838 (40.7) | 793 (36.5) | 217 (33.7) | 4797 (43.6) |
| IV | 456 (25.2) | 321 (17.3) | 414 (9.2) | 173 (8.0) | 106 (16.5) | 1470 (13.4) |
| Missing | 1336 (42.3) | 1080 (36.8) | 2338 (34.1) | 779 (26.4) | 511 (44.2) | 6044 (35.5) |
| Cohort size at initiation (patients) | ||||||
| <7500 | 441 (14.0) | 467 (15.9) | 968 (14.1) | 339 (11.5) | 233 (20.2) | 2448 (14.4) |
| 7500–7999 | 595 (19.0) | 571 (19.5) | 1453 (21.2) | 460 (15.6) | 146 (12.6) | 3226 (18.9) |
| 8000–9899 | 812 (25.8) | 629 (21.4) | 1387 (30.2) | 430 (14.6) | 218 (18.9) | 3476 (20.4) |
| 9900–11 499 | 781 (24.8) | 730 (24.9) | 1639 (23.9) | 843 (28.5) | 137 (11.9) | 4130 (24.2) |
| ≥11 550 | 515 (16.4) | 537 (18.3) | 1403 (20.5) | 882 (29.9) | 421 (36.5) | 3758 (22.1) |
| Rate of scale up (patients/month) | ||||||
| <130 | 735 (23.4) | 727 (24.8) | 1573 (23.0) | 334 (11.3) | 172 (15.0) | 3542 (20.8) |
| 130–159 | 557 (17.7) | 581 (19.8) | 1395 (20.4) | 487 (16.5) | 276 (23.9) | 3296 (19.3) |
| 160–179 | 525 (16.7) | 524 (17.9) | 1438 (21.0) | 745 (25.2) | 284 (24.6) | 3516 (20.6) |
| 180–199 | 464 (14.8) | 530 (18.1) | 1364 (19.9) | 1022 (34.6) | 320 (27.7) | 3700 (21.7) |
| ≥200 | 864 (27.5) | 572 (19.5) | 1080 (15.8) | 366 (12.4) | 102 (8.8) | 2984 (17.5) |
Italics denotes missing data.